Milestone Pharmaceuticals Inc.
NMS: MISTLive Quote
About Milestone Pharmaceuticals Inc.
Healthcare
Biotechnology
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
📊 Fundamental Analysis
Milestone Pharmaceuticals Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -229.7%, which indicates that capital utilization is currently under pressure.
At a current price of $2.02, MIST currently sits at the 55th percentile of its 52-week range (Range: $0.77 - $3.06).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$150.64M
Trailing P/E
--
Forward P/E
-2.36
Beta (5Y)
0.69
52W High
$3.06
52W Low
$0.77
Avg Volume
2.27M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App